R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Articles

HCC: Applying Recent Data Into Practice

July 13th 2020

HCC: Emerging Therapies Under Investigation

July 13th 2020

Combination Regimens for HCC Treatment

July 13th 2020

Emerging Biomarkers in Hepatocellular Carcinoma

July 13th 2020

HCC: Liver Function and Treatment Decisions

July 13th 2020

Safety Profiles of Novel Therapies for HCC

July 13th 2020

Sequencing of Novel Therapies in HCC

July 13th 2020

Regorafenib or Cabozantinib for Second-Line HCC

July 13th 2020

Selecting Second-Line Therapy for HCC

July 13th 2020

Second-Line Treatment for Hepatocellular Carcinoma

July 13th 2020

Novel Combinations to Treat HCC

July 13th 2020

Immunotherapy in Liver Cancer

July 13th 2020

HCC: Treating Patients With Atezolizumab/Bevacizumab

July 13th 2020

IO and VEGF Inhibition in Hepatocellular Carcinoma

July 13th 2020

Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma

July 13th 2020

Locoregional and Systemic Therapy for HCC

July 13th 2020

Hepatocellular Carcinoma: Diagnostic Work-Up

July 13th 2020

Surveillance for Hepatocellular Carcinoma

July 13th 2020

Incidence of Liver Cancer in the US

July 13th 2020